Company intelligence / Profile preview
Campbell Neurosciences
Elk City, Idaho, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Campbell Neurosciences has shown preclinical efficacy of its CampbellCell stem cell product in animal models of schizophrenia and bipolar disorder, as well as successful clinical validation of its saliva-based suicide risk diagnostic; no human clinical efficacy has yet been reported for its therapies but its diagnostic test has undergone clinical studies demonstrating high discrimination among risk groups.
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Cell therapyDiagnosticsNutraceutical
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Therapeutic Solutions International
Beyond the preview
Go deeper on Campbell Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Campbell Neurosciences.